‘Not Yet But Shortly’: EU Remdesivir Filing
The European Medicines Agency has provided an update on the status of its review of Gilead’s investigational antiviral in the treatment of COVID-19.
You may also be interested in...
The much-anticipated EU filing for Gilead’s COVID-19 treatment is being reviewed quickly by the European Medicines Agency.
The European Medicines Agency’s clinical data publication policy is on hold, but calls are growing for the regulator to start publishing trial data for COVID-19 treatments and vaccines as soon as they are authorized in the EU.
Coronavirus Update: Setback With Hydroxychloroquine, Slowdown In UK ADR Reports, But Novel Drugs Begin Trials
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.